Market Cap
zł380.4m
Last Updated
2020/06/03 21:40 UTC
Data Sources
Company Financials
Executive Summary
BIOTON S.A., a biotechnological company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, and other pharmaceutical products in Poland and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Adequate balance sheet and fair value.
Share Price & News
How has BIOTON's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIO's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-2.4%
BIO
-2.5%
PL Biotechs
3.7%
PL Market
1 Year Return
4.4%
BIO
60.2%
PL Biotechs
-16.4%
PL Market
Return vs Industry: BIO underperformed the Polish Biotechs industry which returned 61.1% over the past year.
Return vs Market: BIO exceeded the Polish Market which returned -17.9% over the past year.
Shareholder returns
| BIO | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.4% | -2.5% | 3.7% |
| 30 Day | 16.6% | 2.6% | 9.7% |
| 90 Day | 44.8% | 52.3% | -2.9% |
| 1 Year | 4.4%4.4% | 60.5%60.2% | -14.4%-16.4% |
| 3 Year | -15.6%-15.6% | 22.6%22.4% | -20.5%-26.0% |
| 5 Year | -22.4%-22.4% | -9.8%-11.6% | -16.3%-26.4% |
Price Volatility Vs. Market
How volatile is BIOTON's share price compared to the market and industry in the last 5 years?
Simply Wall St News
9 months ago | Simply Wall St
Some BIOTON (WSE:BIO) Shareholders Have Copped A Big 54% Share Price Drop10 months ago | Simply Wall St
Do Institutions Own BIOTON S.A. (WSE:BIO) Shares?1 year ago | Simply Wall St
The BIOTON (WSE:BIO) Share Price Is Down 55% So Some Shareholders Are Wishing They SoldValuation
Is BIOTON undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BIO (PLN4.43) is trading below our estimate of fair value (PLN16.48)
Significantly Below Fair Value: BIO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BIO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BIO is unprofitable, so we can't compare its PE Ratio to the Polish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIO is good value based on its PB Ratio (0.6x) compared to the PL Biotechs industry average (5.9x).
Next Steps
Future Growth
How is BIOTON forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
34.1%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIOTON has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine whether BIOTON is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- BIOTON competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has BIOTON performed over the past 5 years?
30.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIO is currently unprofitable.
Growing Profit Margin: BIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIO is unprofitable, but has reduced losses over the past 5 years at a rate of 30.4% per year.
Accelerating Growth: Unable to compare BIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).
Return on Equity
High ROE: BIO has a negative Return on Equity (-25.13%), as it is currently unprofitable.
Next Steps
Financial Health
How is BIOTON's financial position?
Financial Position Analysis
Short Term Liabilities: BIO's short term assets (PLN147.9M) do not cover its short term liabilities (PLN168.8M).
Long Term Liabilities: BIO's short term assets (PLN147.9M) exceed its long term liabilities (PLN133.9M).
Debt to Equity History and Analysis
Debt Level: BIO's debt to equity ratio (20.9%) is considered satisfactory.
Reducing Debt: BIO's debt to equity ratio has increased from 11.9% to 20.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BIO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BIO is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 36.9% per year.
Next Steps
Dividend
What is BIOTON's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIO's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.5yrs
Average board tenure
CEO
Robert Neymann
3.08yrs
Tenure
Mr. Robert Neymann has been President of the Management Board at BIOTON S.A. since July 4, 2017. Mr. Neymann served as the President of the Management Board at Harper Hygienics S.A., since 2007 until May 1 ...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice President of the Supervisory Board | no data | no data | no data | |
| Member of the Supervisory Board | no data | no data | no data | |
| Member of the Supervisory Board | no data | no data | no data | |
| Vice-President of Supervisory Board | 3.08yrs | no data | no data | |
| Member of Supervisory Board | 4.33yrs | no data | no data | |
| Member of Supervisory Board | 4yrs | no data | no data | |
| Chairman of the Supervisory Board | 0.50yr | no data | no data |
3.5yrs
Average Tenure
46yo
Average Age
Experienced Board: BIO's board of directors are considered experienced (3.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
BIOTON S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: BIOTON S.A.
- Ticker: BIO
- Exchange: WSE
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: zł380.378m
- Shares outstanding: 85.86m
- Website: https://www.bioton.pl
Number of Employees
Location
- BIOTON S.A.
- ul. Poznanska 12
- Macierzysz
- Ozarów Mazowiecki
- 05-850
- Poland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BIO | WSE (Warsaw Stock Exchange) | Yes | Common Bearer Shares | PL | PLN | Jul 2005 |
| 0DTR | LSE (London Stock Exchange) | Yes | Common Bearer Shares | GB | PLN | Jul 2005 |
Biography
BIOTON S.A., a biotechnological company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, and other pharmaceutical products in Poland and internationally. The company offers recombinant human insulin in pharmaceutical substance form and as preparations for injections; and oral hypoglycemic drugs, including glimepiride and metformin. It also provides FOOT CREAM prodiab that is used for the treatment of dry and atopic skin; HEALTHY EYES prodiab, a dietary supplement for the proper functioning of the eye; Healthy Heart prodiab, a dietary supplement for the proper functioning of the heart and the cardiovascular system; HEALTHY HEART PLUS prodiab, a dietary supplement for the proper functioning of the heart and circulatory system; and VITAMINS AND MINERALS prodiab, a dietary supplement for the cardiovascular system. In addition, the company offers an OTC products line focusing on diet supplements, nutritional uses, and cosmetics for patients with metabolic syndrome and diabetes health problems; and BIOTON FOR HEALTH line of natural ingredients. Further, it is involved in the advertising and advisory activities. The company is based in Ozarów Mazowiecki, Poland.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/03 21:40 |
| End of Day Share Price | 2020/06/03 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.